Review

Therapeutic implications of osteoprotegerin

Sofia Fili¹ , Maria Karalaki¹ and Bernhard Schaller²

¹  Medical School, National and Kapodistrian University of Athens, Athens, Greece

²  Medical School, University of Oradea, Romania

author email corresponding author email

Cancer Cell International 2009, 9:26doi:10.1186/1475-2867-9-26

Published:	12 September 2009

Abstract

Osteoprotegerin (OPG), a member of the tumor necrosis factor (TNF) receptor superfamily, contributes determinatively to the bone remodeling as well as to the pathogenetic mechanism of bone malignancies and disorders of mineral metabolism. There is additional evidence that OPG can promote cell survival by inhibiting TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. A number of recent in vitro, in vivo and clinical studies have defined the role of the RANK/RANKL/OPG pathway in skeletal and vascular diseases. These works were the milestone of the deep understanding of the mechanism of OPG. This review provides an overview of the potential innovative therapeutic strategies of OPG in metastatic breast and prostate carcinoma, multiple myeloma, postmenopausal osteoporosis, glucocorticoid-induced osteoporosis and rheumatoid arthritis. Special reference is given to the increasing evidence that RANKL and OPG may link the skeletal with the vascular system.